The changes of subtype markers between first and second primary breast cancers
Cancer Medicine · 2023
DOI: 10.1002/cam4.5979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Chenyang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Breast Cancer Prevention and Therapy…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Previous studies investigated the changes of subtype markers [estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)] in several clinical settings, but not for second primary breast cancer (SPBC) after first primary breast cancer (FPBC).
Methods
A total of 15,390 patients with SPBC were preliminarily selected from the Surveillance, Epidemiology, and End Results Program, and 3777 patients with complete information on three subtype markers in both FPBC and SPBC were included in the final analyses. The changes of subtype markers and their prognostic implications and potential influential factors were well investigated.
Results
The overall change rates of ER, PR, and HER2 between FPBC and SPBC were 23.0% (867/3777), 35.0% (1322/3777), and 18.3% (691/3777), respectively. Gains of ER, PR, and HER2 after negative index markers were 48.7% (364/748), 37.9% (418/1103), and 11.5% (370/3211), while losses of markers after positive index markers were 16.6% (503/3029), 33.8%(904/2674), and 56.7%(321/566). Loss of ER was significantly associated with increased mortality (18.1% vs. 7.9%, p < 0.001), while gain of ER was significantly associated with decreased mortality (11.5% vs. 23.2%, p < 0.001). Similar results were observed for changes of PR status. However, loss of HER2 was significantly associated with decreased mortality (8.7% vs. 16.3%, p = 0.014), and no significant association was observed between the gain of HER2 and the prognosis of SPBC. Multivariate competing risk analyses showed similar results. HER2 status in FPBC, chemotherapy, and radiotherapy was significantly associated with changes of ER/PR (all p < 0.05), and no available therapies associated with HER2 change.
Conclusion
The changes of subtype markers are observed in a considerable proportion of patients and has statistically significant prognostic implications. Biopsies should be taken as a routine procedure for better therapy management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, National Clinical Research Center for Cancer,…
- Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
ORCID-Profile: Fengju Song
Zitieren
APA
Li, C., Lyu, Z., Wang, Z., Hao, C., Huang, Y., & Song, F. (2023). The changes of subtype markers between first and second primary breast cancers. Cancer Medicine. https://doi.org/10.1002/cam4.5979
Vancouver
Li C, Lyu Z, Wang Z, Hao C, Huang Y, Song F. The changes of subtype markers between first and second primary breast cancers. Cancer Medicine. 2023. doi:10.1002/cam4.5979
BibTeX
@article{Li2023,
author = {Li, Chenyang and Lyu, Zhangyan and Wang, Zhipeng and Hao, Chunfang and Huang, Yubei and Song, Fengju},
title = {The changes of subtype markers between first and second primary breast cancers},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5979}
}
EUVIMED